Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets the KRAS G12D mutation, which is one of the most common oncogenic driver mutations and has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials in China for the treatment of non-small cell lung cancer (NSCLC) [1]
新股消息 | 泰励生物递表港交所
智通财经网·2026-01-29 22:49